Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.64) EPS for the quarter, topping the Zacks' consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million for the quarter, compared to analyst estimates of $7.50 million. View Paratek Pharmaceuticals' Earnings History.

8 equities research analysts have issued twelve-month price targets for Paratek Pharmaceuticals' stock. Their forecasts range from $23.00 to $56.00. On average, they expect Paratek Pharmaceuticals' share price to reach $39.50 in the next twelve months. View Analyst Ratings for Paratek Pharmaceuticals.

Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (8/8/2017)
• 2. Cantor Fitzgerald analysts commented, "OASIS-2 study met all of its primary and secondary endpoints required to support approval for this indication by the FDA and EMA. This represents the third positive Phase 3 registration study of omadacycline (the other two were skin and pneumonia)." (7/17/2017)
• 3. Robert W. Baird analysts commented, "Though sarecycline is not a key driver, it provides a potential source of non-dilutive financing and further validates Paratek's ability to develop a once daily, well tolerated, tetracycline-derived antibiotic. Looking ahead, we expect continued momentum with focus on key upcoming data readouts from two Phase 3 studies of omadacycline in 2Q17, supporting filing in 1H18, and we reiterate our Outperform rating." (3/27/2017)

Some companies that are related to Paratek Pharmaceuticals include NeuroDerm (NDRM), Dermira (DERM), Omeros Corporation (OMER), Xencor (XNCR), Retrophin (RTRX), Epizyme (EPZM), Ascendis Pharma A/S (ASND), Dynavax Technologies Corporation (DVAX), Sangamo Therapeutics (SGMO), Five Prime Therapeutics (FPRX), Amarin Corporation PLC (AMRN), Aduro Biotech (ADRO), Keryx Biopharmaceuticals (KERX), Insmed (INSM), Achaogen (AKAO), PTC Therapeutics (PTCT), ZIOPHARM Oncology (ZIOP) and Flexion Therapeutics (FLXN).

Paratek Pharmaceuticals' management team includes the folowing people:

• Michael F. Bigham CPA, Chairman of the Board, Chief Executive Officer
• Evan Loh M.D., President, Chief Operating Officer, Chief Medical Officer, Director
• Douglas W Pagan, Chief Financial Officer
• William M. Haskel, Senior Vice President, General Counsel, Corporate Secretary
• Regina D. Paglia, Senior Vice President - Human Resources
• Jeanne Jew, Senior Vice President - Business Development
• Evan Tzanis, Senior Vice President - Clinical Development and Clinical Operations
• Rajesh Padmanabhan, Vice President - Information Technology
• Stephen Villano M.D., Vice President - Clinical and Medical Affairs
• Adam Woodrow, Vice President and Chief Commercial Officer

Paratek Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Omega Fund Management LLC (9.46%), FMR LLC (5.30%), Vanguard Group Inc. (3.14%), State Street Corp (2.22%), Renaissance Technologies LLC (2.16%) and Tekla Capital Management LLC (1.92%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega and Michael Bigham. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Paratek Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Tekla Capital Management LLC, Nexthera Capital LP, Balyasny Asset Management LLC, Boston Partners, Essex Investment Management Co. LLC and Victory Capital Management Inc.. Company insiders that have sold Paratek Pharmaceuticals stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

Paratek Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Pictet Asset Management Ltd., State Street Corp, Numeric Investors LLC, Franklin Resources Inc., JPMorgan Chase & Co., Renaissance Technologies LLC and Nicholas Investment Partners LP. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Evan Loh, Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $19.05.